Essa Pharma Inc Reports Results For The Quarter Ended In March: Earnings Summary

ESSA Pharma

14/05/2024 15:22

* ESSA Pharma Inc  EPIX.OQ  reported a quarterly adjusted
loss
of 20 cents​​ per share for the quarter ended in March, lower
than the same quarter last year, when the company reported EPS
of -16 cents.  The mean expectation of five analysts for the
quarter was for a loss of 19 cents per share. Wall Street
expected results to range from -24 cents to -15 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * ESSA Pharma Inc's reported EPS for the quarter was a loss
of 20
cents​.
    * The company reported a quarterly loss of $8.99 million.
    * ESSA Pharma Inc shares had fallen by 30.2% this
quarter and
lost 10.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 1.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for ESSA Pharma Inc
is $17.00 
This summary was machine generated from LSEG data May 14 at
02:22 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.19          -0.20          Missed
 Dec. 31 2023      -0.17          -0.14          Beat
 Sep. 30 2023      -0.21          -0.12          Beat
 Jun. 30 2023      -0.19          -0.17          Beat